Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines focusing on central nervous system disorders. The company has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.

Advanced Micro Devices is a semiconductor company. The company primarily provides x86 microprocessors, as standalone devices or as incorporated into an accelerated processing unit, chipsets, graphics processing units (GPUs), data center and personnel GPUs, and development services; server and embedded processors, semi-custom System-on-Chip products, development services and technology for game consoles. The company also licenses portions of its intellectual property portfolio. The company's segments are: Computing and Graphics, which consists of desktop, notebooks, commercial, and chipsets products; and Enterprise, Embedded and Semi-Custom, which includes server processors, and embedded P\processors products.

Alexion Pharmaceuticals is a biopharmaceutical company serving patients and families affected by rare diseases through the discovery, development and commercialization of therapies. The company has developed and commercialized two complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder in patients who are anti-aquaporin-4 antibody positive. In addition, the company has two enzyme replacement therapies for metabolic disorders, hypophosphatasia and lysosomal acid lipase deficiency.

Allogene Therapeutics is a clinical stage immuno-oncology company focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. Several of the company's key product candidates, including UCART19, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell driven hematological malignancies. The company is developing an anti-CD52 monoclonal antibody, ALLO-647, which is designed to be used prior to infusing its other product candidates as part of the lymphodepletion regimen.

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company developing therapeutics based on RNA interference (RNAi). RNAi is a biological pathway within cells for sequence-specific silencing and regulation of gene expression. The company has two RNAi-based medicines, ONPATTRO? (patisiran) and GIVLAARI? (givosiran). ONPATTRO is approved by the United States Food and Drug Administration (FDA) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults and has also been approved in the European Union, Japan, Canada and Switzerland. GIVLAARI is approved by FDA for the treatment of adults with acute hepatic porphyria.

Amazon.com serves consumers through its online and physical stores. The company also manufactures and sells electronic devices, including Kindle, Fire tablet, Fire TV, Echo, and Ring, and the company develops and produces media content. The company operates customer service centers and provides programs that enable sellers to grow their businesses, sell their products in its stores, and fulfill orders through the company The company serves developers and enterprises of various sizes, including start-ups, government agencies, and academic institutions, through its Amazon Web Services segment, which provides a set of global compute, storage, database, and other service offerings. The company also provides services, such as advertising.

Amgen is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. The company's products include: Enbrel? (etanercept), which is used in indications for the treatment of adult patients with moderately to severely active rheumatoid arthritis, patients with chronic moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy and patients with active psoriatic arthritis; and Prolia? (denosumab), which is used for the treatment of postmenopausal women with osteoporosis at high risk of fracture or multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy.

Amicus Therapeutics is a biotechnology company focused on the discovering, developing, and delivering medicines for diseases. The company's Commercial Product and Product Candidates include Galafold? (Migalastat HCl), which is for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; Enzyme Replacement Therapy for Pompe disease; and Cyclin-dependent kinase-like 5 (CDKL5) Deficiency Disorder, which is a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of several essential proteins for normal brain development.

Aravive is clinical-stage biotechnology company focused on developing therapies that target survival pathways for both advanced solid tumors as well as hematologic malignancies. The company's primary therapeutic focus is the GAS6-AXL pathway, where AXL receptor signaling plays a role in multiple types of malignancies by promoting metastasis, cancer cell survival, resistance to treatments, and immune suppression. The U.S. Food and Drug Administration, designated as a Fast Track development program the investigation of the company's primary development candidate, Aravive-S6-500, for platinum-resistant recurrent ovarian cancer.

Barrick Gold is engaged in the production and sale of gold, as well as related activities such as exploration and mine development. Co. also produces copper and hold interests in oil and gas properties located in Canada. Co.'s mining operations are concentrated in three regional business units: North America, South America and Australia Pacific. Co. also hold a 73.9% equity interest in African Barrick Gold plc that owns gold mines and exploration properties in Africa. Co.'s copper business unit contains producing copper mines located in Chile and Zambia; and a mine under construction located in Saudi Arabia.

Cameco and its subsidiaries are engaged in the exploration for and the development, mining, refining, conversion and fabrication of uranium for sale as fuel for generating electricity in nuclear power reactors in Canada and other countries. Co. has three reportable segments: uranium, which explores for, mines, mills, purchases, and sells uranium concentrate; fuel services, which refines, converts and fabricates uranium concentrate, and purchases and sells conversion services; and electricity, which generates and sells electricity through its 31.6% interest in the Bruce Power Limited Partnership, which operates four nuclear reactors and manages the overall site in southern Ontario.

Centene is an insurance holding company. The company's Managed Care segment provides health plan coverage to individuals through government subsidized programs. The company also provides a variety of individual, small group, and large group commercial healthcare products, both to employers and directly to members in the Managed Care segment. The company's Specialty Services segment consists of the company's specialty companies prviding healthcare services and products to state programs, correctional facilities, healthcare organizations, employer groups and other commercial organizations, as well as to its own subsidiaries. The Specialty Service segment also includes the Government Contracts business.

City Office REIT is engaged in acquiring, owning and operating office properties located in the Southern and Western U.S. The company owns office buildings in the metropolitan areas of Dallas, Denver, Orlando, Phoenix, Portland, San Diego and Tampa.

CNX Resources is an independent oil and gas company focused on the exploration, development, production, gathering, processing and acquisition of natural gas properties primarily in the Appalachian Basin. The company's operations are centered on unconventional shale formations, primarily the Marcellus Shale and Utica Shale. The company operates, develops and explores for natural gas in Appalachia (Pennsylvania, West Virginia, Ohio, and Virginia).

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing muscle activators and muscle inhibitors as treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company's clinical-stage drug candidates are: omecamtiv mecarbil, a cardiac myosin activator for the treatment of heart failure, AMG 594, a cardiac troponin activator, reldesemtiv, a skeletal muscle troponin activator for the treatments of spinal muscular atrophy and amyotrophic lateral sclerosis, and CK-3773274, a cardiac myosin inhibitor which is designed to reduce the hypercontractility that is associated with hypertrophic cardiomyopathy.

DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring systems for use by people with diabetes and by healthcare providers. The company's products include: DecCom G6?, which allows the company's transmitter to run an algorithm to generate a glucose value and to communicate to a patient's mobile device; DexCom G4? PLATINUM, which is used to adjust therapy and to educate and motivate patients to modify their behavior after viewing the effects that specific foods, exercise, stress and medications have on their glucose levels; and DexCom Share?, which transmits glucose information to the mobile devices of designated recipients.

Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of subcutaneously delivered ribonucleic acid (RNA) interference (RNAi)-based therapeutics using its GalXC? RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. The company's primary development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus; and an undisclosed product candidate against a rare liver disease, which is in Clinical Trial Application or Investigational New Drug application enabling studies.

Dollar General is a discount retailer. The company's consumables products includes paper and cleaning products, packaged food, perishables, snacks, health and beauty, pet, and tobacco products. The company's seasonal products include decorations, toys, batteries, small electronics, greeting cards, stationery, prepaid phones and accessories, gardening supplies, hardware, automotive and home office supplies. The company's home products include kitchen supplies, cookware, small appliances, light bulbs, storage containers, frames, candles, craft supplies and kitchen, bed and bath soft goods. The company's apparel includes casual everyday apparel, as well as socks, underwear, disposable diapers, shoes and accessories.

DSP Group is a provider of wireless and audio chipsets for a range of smart-enabled devices. The company provides a portfolio of wireless chipsets, including DECT/CAT-iq, ULE, Wi-Fi, PSTN, HDClear?, video and Voice-over-IP (VoIP) technologies. The company is engaged in low-power integrated circuits for audio and voice signal processing applications. The company enables converged voice, audio, video and data connectivity across mobile, consumer and enterprise products, from mobile phones, Internet of Things and wearable devices, connected multimedia screens and home automation and security to cordless phones, VoIP systems and home gateways.

Electromed develops, manufactures, markets and sells products that provide airway clearance therapy, including the SmartVest? Airway Clearance System (SmartVest System) and related products, to patients with compromised pulmonary function. The SmartVest System is available in two models, SV2100 and SQL?. The SmartVest SQL System consists of an inflatable therapy garment, a programmable air pulse generator and a patented single-hose that delivers air pulses from the generator to the garment. The company also markets the Single Patient Use SmartVest? and SmartVest Wrap? to health care providers in the acute care setting.

EQT is a natural gas production company with operations focus in the Marcellus and Utica shales of the Appalachian Basin.

Five9 is a provider of cloud software for contact centers. The company's Virtual Contact Center (VCC), cloud platform and applications, allows simultaneous management and optimization of customer interactions across voice, chat, email, web, social media and mobile channels, either directly or through its application programming interfaces. The company's VCC cloud platform matches each customer interaction with an appropriate agent resource and delivers customer data to the agent in real-time through integrations with adjacent enterprise applications, such as customer relationship management software. The company provides its solution through a software-as-a-service business model with recurring subscriptions.

Humana is a holding company. Through its subsidiaries, the company is a health and well-being company. The company manages its business with three segments: Retail, which consists of products sold on a retail basis to individuals including medical and supplemental benefit plans, such as Medicare and state-based Medicaid Contracts; Group and Specialty, which consists of employer group commercial fully-insured medical and specialty health insurance benefits, including dental, vision and life insurance benefits, as well as administrative services only; and Healthcare Services, which includes pharmacy solutions, provider services, clinical care services, and predictive modeling and informatics services

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. JAKAFI (ruxolitinib) has been approved for the treatment of patients with intermediate or high-risk myelofibrosis, for the treatment of patients with polycythemia vera, and for the treatment of steroid-refractory acute graft-versus-host disease in adult and pediatric patients 12 years and older. The company has also obtained a license to develop and commercialize ICLUSIG (ponatinib) in Europe and other select countries. In the European Union, ICLUSIG is approved for the treatment of adult patients with chronic phase, accelerated phase or blast phase chronic myeloid leukemia.

Inphi is a provider of analog and mixed signal semiconductor solutions for the communications and datacenter markets. The company's analog and mixed signal semiconductor solutions provide an interface between analog and mixed signals and digital information in systems such as telecommunications transport systems, enterprise networking equipment and datacenters. The company has a range of products in its portfolio, including products that have commercially shipped, products for which the company has shipped engineering samples and products under development, that perform a range of functions such as amplifying, encoding, multiplexing, demultiplexing, and retiming signals at speeds up to 400 Gbps.

Kala Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics using its AMPPLIFY? Mucus Penetrating Particles drug delivery technology, with a focus on the treatment of eye diseases. The company's approved ocular corticosteroid product, INVELTYS? (loteprednol etabonate ophthalmic suspension) is used for the treatment of post-operative inflammation and pain. The company is developing KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease. The company is evaluating compounds in its receptor Tyrosine Kinase Inhibitor program that inhibit the vascular endothelial growth factor pathway for the treatment of a number of retinal diseases.

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of the company's proprietary PRINT? technology to transform the lives of patients. The company is focused on the development of two product candidates for which it holds commercial rights: LIQ861, which is for the treatment of pulmonary arterial hypertension, a disease caused by the hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death; and LIQ865, which is an injectable, sustained-release formulation of bupivacaine for the management of local post-operative pain a surgical procedure.

Lockheed Martin is a security and aerospace company. The company has four segments: Aeronautics, which is engaged in the research, design, development, manufacture, integration, sustainment, support and upgrade of military aircraft; Missiles and Fire Control, which provides air and missile defense systems, logistics, fire control systems, and mission operations support; Rotary and Mission Systems, which provides design, manufacture, service and support for military and commercial helicopters, radar systems, and simulation and training services; Space, which researches, designs, develops, engineers and produces satellites, space transportation systems, and strategic, strike, and defensive systems.

MarketAxess Holdings operates an electronic trading platform that enables fixed-income market participants to trade corporate bonds and other types of fixed-income instruments using its patented technology. Through its Open Trading? protocols, the company executes trades in certain bond between and among institutional investor and broker-dealer clients. The company also provides trading-related products and services, including: Composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services.

Moderna is creating a new generation of medicines based on messenger RNA to improve the lives of patients. The company uses its platform to identify and develop new mRNA medicines. When the company identifies a combination of platform technologies or programs across mRNA technologies, delivery technologies, and manufacturing processes that can enable shared product features across multiple potential mRNA medicines, it groups those programs as a modality. The company has created six modalities including prohylactic vaccines; cancer vaccines; intratumoral immuno-oncology; localized regenerative therapeuctics; systemic secreted therapeutics; and systemic intracellular therapeutics.

Molina Healthcare is a holding company. Through its subsidiaries, the company provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces. The company has two segments: Health Plans and Other. The company's health plans are operated by its respective wholly owned subsidiaries in those states, each of which is licensed as a health maintenance organization. The company's business includes: Medicaid, which provides health care and long-term care services and support to low-income Americans; and Medicare, which provides eligible persons age 65 and over and some disabled persons with a variety of hospital, medical insurance, and prescription drug benefits.

Monolithic Power Systems is a fabless semiconductor company. The company designs, develops and markets power solutions for systems found in consumer, computing and storage, automotive, industrial, communications and consumer applications. The company's primary product families include the following: Direct Current (DC) to DC products, which are used to convert and control voltages within a range of electronic systems such as portable electronic devices, wireless Local Area Network access points, computers, and monitors, automobiles and medical equipment; and Lighting Control Products, which include lighting control integrated circuits that are used in backlighting and general illumination products.

Nasdaq is a holding company. Nasdaq is a holding company. Through its subsidiaries, the company manages, operates and provides its products and services in business segments: Market Services, which includes equity derivative trading and clearing, cash equity trading, fixed income and commodities trading and clearing and trade management services businesses; Corporate Services, which includes listing services and corporate solutions businesses; Information Services, which includes market data, index, and investment data and analytics; and Market Technology, which provides and delivers solutions across the trade lifecycle via the Nasdaq Financial Framework.

Newmont is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia and Ghana. The company is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions; North America, South America, Australia, Africa and Nevada.

NVIDIA engages in graphics processing unit (GPU)-based visual computing and accelerated computing platforms. The company has two segments, GPU and Tegra Processor, which are based on a single underlying architecture. The company's GPU product brands are aimed at markets including GeForce for gamers; Quadro for designers; Tesla and DGX for artificial intelligence data scientists and big data researchers; and GRID for cloud-based visual computing users. The company's Tegra brand integrates an entire computer onto a single chip, and incorporates GPUs and multi-core CPUs to drive supercomputing for autonomous robots, drones, and cars, as well as for game consoles and mobile gaming and entertainment devices.

Okta is an independent identity management platform for the enterprise. The Okta Identity Cloud is the company's platform that enables its customers to connect people to technology, anywhere, anytime and from any device. The Okta Identity Cloud consists of a suite of products to manage and secure identities. Products used for workforce identity are consumed through web and mobile interfaces, and provide ways for Information Technology organizations to manage identities for their employees, contractors and partners. The company's products include: Universal Directory; Single Sign-On; Adaptive Multi-Factor Authentication; Lifecycle Management; and Application Programming Interface Access Management.

PetMed Express is a pet pharmacy. The company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. These pet supplies include: food, beds, crates, stairs, strollers, and other pet supplies. The company's non-prescription medications and supplies include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. The company's prescription medications include heartworm and flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other medications, as well as generic substitutes.

Principia Biopharma is a late-stage biopharmaceutical company. The company has produced three new drug candidates from its platform. The company's key drug candidate, PRN1008, is designed to form a reversible covalent bond with the Bruton's Tyrosine Kinase (BTK) enzyme. The second drug candidate in the company's BTK franchise is PRN2246/SAR442168, an irreversible covalent BTK inhibitor that it designed to cross the blood-brain barrier and modulate immune cell function in the brain for the treatment of multiple sclerosis, and potentially other central nervous system. PRN1371, an additional wholly owned drug candidate, is an inhibitor of Fibroblast Growth Factor Receptor designed for the treatment of solid tumors.

QTS Realty Trust is a provider of data center solutions. Through its controlling interest in QualityTech, LP (the Operating Partnership) and the subsidiaries of the Operating Partnership, the company is engaged in the business of owning, acquiring, constructing, redeveloping and managing multi-tenant data centers. The company's data centers are facilities that support its customers' IT infrastructure equipment and provide access and connectivity to a range of communications and IT services providers. The company provides IT solutions including data center space, power and cooling, connectivity and managed services for customers in the financial services, healthcare, retail, government, and technology industries.

Regeneron Pharmaceuticals is a biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of diseases. The company's commercialized medicines and product candidates in development are designed to assist patients with eye disease, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and rare diseases. The company's products include: EYLEA (aflibercept) injection, which is used for the treatment of neovascular age-related macular degeneration, diabetic macular edema; and Dupixent (dupilumab) injection, which is used for the treatment of adult patients with atopic dermatitis.

SBA Communications is a holding company. Through its subsidiaries, the company is an owner and operator of wireless communications infrastructure, including tower structures, rooftops, and other structures that support antennas used for wireless communications. The company's operations are in the U.S. and its territories. In its site leasing business, the company leases antenna space to wireless service providers on towers that the company owns or operates and manages rooftop and tower sites for property owners under various contractual arrangements. In its site development business, the company assists wireless service providers in developing and maintaining their own wireless service networks.

Shopify provides a cloud-based commerce platform designed for small and medium-sized businesses. Merchants use its software to run their business across all of their sales channels, including web, tablet and mobile storefronts, social media storefronts, and brick-and-mortar and pop-up shops. Co. provides a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand and grow its business. Co.'s platform provides merchants with a single view of their business and customers across all of their sales channels and enables them to manage products and inventory, process orders and payments, build customer relationships and leverage analytics and reporting.

SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security market. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The company's primary product is an oral formulation of TPOXX?, an antiviral drug for the treatment of human smallpox disease caused by variola virus. The United States Food and Drug Administration has approved oral TPOXX? for the treatment of smallpox.

Switch is a holding company. Through its subsidiaries, the company is engaged in technology infrastructure powering the sustainable growth of the connected world and the Internet of Everything. The company provides colocation space and related services to global enterprises, financial companies, government agencies, and others that conduct business on the internet. The company develops and operates data centers in Nevada, which are Tier IV Gold certified, and Michigan, and is developing data centers in Georgia, delivering redundant services with low latency and capacity transport environments.

Tesla designs, develops, manufactures, sells and leases electric vehicles and energy generation and storage systems, and provides services related to its products. The company operates as two reportable segments: automotive, which includes the design, development, manufacturing, sales, and leasing of electric vehicles as well as sales of automotive regulatory credits; and energy generation and storage, which includes the design, manufacture, installation, sales, and leasing of solar energy generation and energy storage products, services related to such products, and sales of solar energy system incentives.

United Therapeutics is a biotechnology company. The company markets and sells four commercial therapies to treat pulmonary arterial hypertension (PAH): Remodulin? (treprostinil) Injection; Tyvaso? (treprostinil) Inhalation Solution; Orenitram? (treprostinil) Extended-Release Tablets; and Adcirca? (tadalafil) Tablets. The company also markets and sells an oncology product, Unituxin? (dinutuximab) Injection for treatment of high-risk neuroblastoma. The company also engages in research and development of new indications and formulations and delivery devices for its existing products, as well as new products to treat PAH and other conditions. The company also engages in organ transplantation-related technologies.

Veeva Systems provides industry cloud solutions for the life sciences industry. Veeva Commercial Cloud is a suite of multichannel customer relationship management applications, a commercial data warehouse, territory allocation and alignment applications, master data management applications and customer reference and data and services. Veeva Vault is the company's suite of cloud-based, enterprise content management applications that address the content management requirements for the company's customers'commercial functions, including medical and sales and marketing, and key research and development functions, including clinical, regulatory, quality, and, when available, safety.

Verisign is a provider of domain name registry services and internet infrastructure, enabling internet navigation for domain names. The company enables the security, stability, and resiliency of main internet infrastructure and services, including providing root zone maintainer services, operating internet root servers, and providing registration services and authoritative resolution for the .com and .net top-level domains, which support the majority of global e-commerce. The company operates the authoritative directory of and/or the back-end systems for all .com, .net, .cc, .tv, .gov, .jobs, .edu and .name domain names, among others. The company also provides internationalized domain name services.

Werner Enterprises is a transportation and logistics company engaged primarily in transporting truckload shipments of general commodities in both interstate and intrastate commerce. The company has two reportable segments: Truckload Transportation Services, which includes the medium-to-long-haul van fleet that transports a variety of consumer nondurable products and other commodities in truckload quantities over irregular routes using dry van trailers, the expedited fleet that provides truckload services, and the regional short-haul fleet that provides truckload van service across the U.S; and Werner Logistics, which is a non-asset-based transportation and logistics provider.

Wheaton Precious Metals is engaged in the silver mining business.